AYLA

Ayala Pharmaceuticals, Inc. Common Stock
AYLA

Delisted

AYLA was delisted on the 18th of January, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in Ayala Pharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

15.95% less ownership

Funds ownership: 15.95% → 0% (-16%)

100% less funds holding

Funds holding: 11 → 0 (-11)

100% less capital inflows, than outflows

Capital inflows: $0 | Capital outflows: $946K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 11

Holders
–
Holders Change
-11
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
HIIFS
Harel Insurance Investments & Financial Services
Israel
-$862K
2
BCM
Bridgeway Capital Management
Texas
-$23.9K
3
Renaissance Technologies
Renaissance Technologies
New York
-$21K
4
PVH
Psagot Value Holdings
Israel
-$14K
5
TSS
Two Sigma Securities
New York
-$6.43K

AYLA Hedge Fund Activity: Q1 2023 in Review

0 of the 6,287 institutional investors tracked by Wall St. Rank reported a position in Ayala Pharmaceuticals, Inc. Common Stock (AYLA) for Q1 2023, worth a combined $0 — down 100% from $946K a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of AYLA and 0 opened new positions — a net loss of 11 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Harel Insurance Investments & Financial Services, exiting entirely with an estimated $862K sold.

  • 0 institutional investors held Ayala Pharmaceuticals, Inc. Common Stock (AYLA) as of Q1 2023, down from 11 in Q4 2022.
  • Funds reported $0 of Ayala Pharmaceuticals, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new Ayala Pharmaceuticals, Inc. Common Stock positions in Q1 2023 and 11 closed out, a net change of -11 holders.
  • The largest Ayala Pharmaceuticals, Inc. Common Stock seller in Q1 2023 was Harel Insurance Investments & Financial Services, an estimated $862K sold.

Based on aggregated 13F filings for Q1 2023.